What This Site Is
CJC + Ipa Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 ipamorelin — a two-component growth hormone secretagogue blend studied in human, rodent, and multi-species models across more than two decades of endocrinology research. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "store" in the domain name is an archive reference — the holdings of a curated library of studies, sorted like a folk-art almanac. This site does not sell, fulfill, or process orders for any compound. It is an indexed reading room for the 22 numbered findings and 4 recent-studies entries in the CJC-1295 ipamorelin peer-reviewed record.
The "clinic," "doctor," "store," and "rx" modifiers that appear in domain names across the editorial portfolio are positional references — they describe the site's relationship to the literature (a clinic's diagnostic depth, a doctor's explanatory register, an archivist's curated shelf), not the site's services. No healthcare services, clinical consultations, or prescriptions are provided here or anywhere on this domain.
Editorial Methodology
Every quantitative claim on this site is sourced to a numbered citation in the References index. Citations are drawn from PubMed-indexed journals, ClinicalTrials.gov, and peer-reviewed pharmacology and endocrinology literature. The research record covers findings from 1998 (Raun et al. ipamorelin selectivity paper) through 2025 (tesamorelin meta-analysis). All claims are attributed to the species and study design in which they were measured.
This site does not cite preprints, promotional literature, manufacturer white papers, or community anecdotes. Where the peer-reviewed evidence base is thin (e.g., published human half-life data for ipamorelin), the site states the gap explicitly. Where findings derive from animal models, the species and model are identified. The almanac is not a clinical protocol; it is an indexed record of what controlled studies have measured.
Regulatory Status of CJC-1295 and Ipamorelin
FDA / WADA STATUS
Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. Both are prohibited by WADA under Section S2 of the Prohibited List. See full details below.
Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. CJC-1295 (with DAC) reached Phase I/II-context human studies published in 2006–2009 through ConjuChem Inc. Ipamorelin was studied in Phase I/II for postoperative ileus (NCT00672074, Rhythm Pharmaceuticals/Helsinn) and in a small Phase I safety study. Neither compound has completed Phase III trials.
Both compounds appear on the WADA Prohibited List: CJC-1295 as a GHRH analog (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics) and ipamorelin as a growth hormone secretagogue (GHS-R1a agonist, Section S2). Both may additionally fall under Section S0 Non-Approved Substances.
As of December 2024 FDA Pharmacy Compounding Advisory Committee briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List for compounding under section 503A of the FD&C Act. Ipamorelin's compounding status is under ongoing evaluation.
EST. 06 — REGULATORY STATUS MATRIX
Editorial Disclaimer
This site is an editorial digest of peer-reviewed scientific literature. It is not a source of medical advice, clinical guidance, or treatment recommendations. No content on this site should be construed as recommending the acquisition, preparation, or administration of any compound. Consult a qualified healthcare professional for any medical concern.
The editorial voice on this site describes research findings in the species and contexts in which they were measured. Rodent findings are attributed to rodent models. Human findings are attributed to their trial populations. No finding is extrapolated to a personal recommendation.